137 related articles for article (PubMed ID: 16886664)
1. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
2. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells.
Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780
[TBL] [Abstract][Full Text] [Related]
4. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
5. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
8. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.
Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
10. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
[TBL] [Abstract][Full Text] [Related]
11. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1alpha,25(OH)2D3 targets.
Dunlop TW; Väisänen S; Frank C; Carlberg C
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):257-60. PubMed ID: 15225781
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis.
Bremmer F; Thelen P; Pottek T; Behnes CL; Radzun HJ; Schweyer S
Anticancer Res; 2012 Jan; 32(1):341-9. PubMed ID: 22213325
[TBL] [Abstract][Full Text] [Related]
13. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines.
Pospechova K; Rozehnal V; Stejskalova L; Vrzal R; Pospisilova N; Jamborova G; May K; Siegmund W; Dvorak Z; Nachtigal P; Semecky V; Pavek P
Mol Cell Endocrinol; 2009 Feb; 299(2):178-87. PubMed ID: 19133314
[TBL] [Abstract][Full Text] [Related]
16. Identification of VDR-responsive gene signatures in breast cancer cells.
Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns.
Doig CL; Singh PK; Dhiman VK; Thorne JL; Battaglia S; Sobolewski M; Maguire O; O'Neill LP; Turner BM; McCabe CJ; Smiraglia DJ; Campbell MJ
Carcinogenesis; 2013 Feb; 34(2):248-56. PubMed ID: 23087083
[TBL] [Abstract][Full Text] [Related]
18. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3.
Malinen M; Saramäki A; Ropponen A; Degenhardt T; Väisänen S; Carlberg C
Nucleic Acids Res; 2008 Jan; 36(1):121-32. PubMed ID: 17999998
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D receptor in cancer.
Thorne J; Campbell MJ
Proc Nutr Soc; 2008 May; 67(2):115-27. PubMed ID: 18412986
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor.
Saramäki A; Banwell CM; Campbell MJ; Carlberg C
Nucleic Acids Res; 2006; 34(2):543-54. PubMed ID: 16434701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]